BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Receptor for advanced glycation endproducts (RAGE)

October 6, 2016 7:00 AM UTC

Mouse studies suggest inhibiting RAGE could help treat stroke that occurs in patients with hyperglycemia. In a hyperglycemic mouse model of ischemic stroke, RAGE knockout decreased infarct volume compared with normal RAGE expression. Next steps could include testing RAGE inhibitors in the model.

vTv Therapeutics Inc. has the RAGE antagonist azeliragon (TTP488; PF-04494700; PF-4494700) in Phase III testing for Alzheimer's disease...